2023
Factors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use
Bahji A, Gordon K, Crystal S, Satre D, Wiliams E, Edelman E, Justice A. Factors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use. AIDS And Behavior 2023, 27: 2455-2462. PMID: 36622487, PMCID: PMC10225332, DOI: 10.1007/s10461-022-03972-3.Peer-Reviewed Original Research
2022
Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus
Oursler KK, Marconi VC, Wang Z, Xu K, Montano M, So-Armah K, Justice AC, Sun YV. Epigenetic Age Acceleration Markers Are Associated With Physiologic Frailty and All-Cause Mortality in People With Human Immunodeficiency Virus. Clinical Infectious Diseases 2022, 76: e638-e644. PMID: 35970820, PMCID: PMC10169393, DOI: 10.1093/cid/ciac656.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusPhysiologic frailtyVACS IndexCause mortalityMortality discriminationImmunodeficiency virusAge accelerationEpigenetic age accelerationVeterans Aging Cohort Study (VACS) IndexWhite blood cell samplesVACS Index 2.0VACS Index scoreNon-Hispanic blacksIntrinsic epigenetic age accelerationExtrinsic epigenetic age accelerationEpigenome-wide DNA methylationBlood cell samplesHazard ratioOne-year increaseCox regressionMean ageC-statisticIndex scoreMortalityStudy indices
2021
Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America
McGinnis KA, Justice AC, Moore RD, Silverberg MJ, Althoff KN, Karris M, Lima VD, Crane HM, Horberg MA, Klein MB, Gange SJ, Gebo KA, Mayor A, Tate JP, Benson C, Bosch R, Kirk G, Marconi V, Colasanti J, Mayer K, Grasso C, Hogg R, Lima V, Montaner J, Sereda P, Salters K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Jacobson J, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Smith G, Loutfy M, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, McGinnis K, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America. Clinical Infectious Diseases 2021, 75: 297-304. PMID: 34609485, PMCID: PMC9410720, DOI: 10.1093/cid/ciab883.Peer-Reviewed Original ResearchConceptsNorth American AIDS Cohort CollaborationVACS Index 2.0National Death IndexHIV-1 RNAHuman immunodeficiency virusCopies/mLRisk of mortalityRace/ethnicityCohort CollaborationNA-ACCORDCause mortalityCD4 countMedian ageDeath IndexImmunodeficiency virusPredicting MortalityMortality ascertainmentMortality rateMortalitySpecific biomarkersPWHDiverse cohortObserved mortalityCohortHIV
2020
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018
Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill M, Sterling T, Rebeiro P, Lima V, Mayor A, Silverberg M, Horberg M, Moore R, Althoff K, Benson C, Bosch R, Emory-Grady G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Johns R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Crouzat F, Loutfy M, Smith G, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Hunter-Mellado R, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, Park L, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases 2020, 73: e2334-e2337. PMID: 33383586, PMCID: PMC8492212, DOI: 10.1093/cid/ciaa1904.Peer-Reviewed Original ResearchDNA methylation mediates the effect of cocaine use on HIV severity
Shu C, Justice AC, Zhang X, Wang Z, Hancock DB, Johnson EO, Xu K. DNA methylation mediates the effect of cocaine use on HIV severity. Clinical Epigenetics 2020, 12: 140. PMID: 32928285, PMCID: PMC7491141, DOI: 10.1186/s13148-020-00934-1.Peer-Reviewed Original ResearchConceptsHIV-positive participantsHIV severityVACS IndexCocaine useCocaine effectsVeterans Aging Cohort Study Biomarker CohortVeterans Aging Cohort Study (VACS) IndexEpigenome-wide associationHuman immunodeficiency virus (HIV) progressionHigher VACS indexFrequent cocaine useCandidate CpG sitesPersistent cocaine useMendelian randomization analysisHIV outcomesBiomarker cohortHIV progressionVirus progressionVAC indexVeteran populationAntiviral responseCandidate mediatorsStudy indicesMR analysisSeverityThe Veterans Aging Cohort Study (VACS) Index Predicts Mortality in a Community-recruited Cohort of People With Human Immunodeficiency Virus (HIV) Who Use Illicit Drugs
Reddon H, Grant C, Nosova E, Fairbairn N, Barrios R, Justice AC, Nolan S, Socias ME, Milloy MJ. The Veterans Aging Cohort Study (VACS) Index Predicts Mortality in a Community-recruited Cohort of People With Human Immunodeficiency Virus (HIV) Who Use Illicit Drugs. Clinical Infectious Diseases 2020, 73: 538-541. PMID: 32857842, PMCID: PMC8496478, DOI: 10.1093/cid/ciaa1263.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusVeterans Aging Cohort Study (VACS) IndexHuman immunodeficiency virus (HIV) disease severityStudy indicesCommunity-recruited cohortIllicit drugsVirus disease severityVACS IndexProspective cohortImmunodeficiency virusClinical biomarkersDisease severityStudy periodCohortMortalityDrugsIndexBiomarkersSeverityTiming of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus
Silverberg MJ, Leyden W, Hernández-Ramírez RU, Qin L, Lin H, Justice AC, Hessol NA, Achenbach CJ, D’Souza G, Engels EA, Althoff KN, Mayor AM, Sterling TR, Kitahata MM, Bosch RJ, Saag MS, Rabkin CS, Horberg MA, Gill MJ, Grover S, Mathews WC, Li J, Crane HM, Gange SJ, Lau B, Moore RD, Dubrow R, Neugebauer RS. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clinical Infectious Diseases 2020, 72: 1900-1909. PMID: 32785640, PMCID: PMC8315132, DOI: 10.1093/cid/ciaa1046.Peer-Reviewed Original ResearchConceptsVirus-related cancersEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapyART initiationImmunodeficiency virusNorth American AIDS Cohort CollaborationART-naive PLWHEarly ART initiationAntiretroviral therapy initiationHIV transmission riskNon-Hodgkin lymphomaCancer registry linkageRisk of cancerMarginal structural modelsRace/ethnicityCohort CollaborationTherapy initiationChart reviewIncident cancerRegistry linkageViral hepatitisTime-dependent confoundingCancer groupViral etiologyPolypharmacy in HIV: recent insights and future directions.
Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Current Opinion In HIV And AIDS 2020, 15: 126-133. PMID: 31833963, PMCID: PMC7543953, DOI: 10.1097/coh.0000000000000608.Commentaries, Editorials and LettersConceptsSeverity of illnessInappropriate medicationsDrug interactionsActual adverse eventsSubstance useTotal drug burdenMechanism of injuryElectronic health recordsNonantiretroviral medicationsUpdate findingsMore medicationsAdverse eventsDrug burdenClinical managementPolypharmacyDirect biomarkerMedicationsModifiable mechanismsPWHSicker individualsHealth recordsStrong associationHIVInjuryIllness
2019
HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status
Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Gibert CL, Bräu N, Brown ST, Roy JA, Taddei TH, Justice AC, Re V. HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. Journal Of The National Cancer Institute 2019, 112: 747-755. PMID: 31687755, PMCID: PMC7357318, DOI: 10.1093/jnci/djz214.Peer-Reviewed Original ResearchConceptsRisk of HCCHigher HIV RNAHCC risk factorsHIV RNAHIV viremiaHepatocellular carcinomaBaseline cirrhosisCirrhosis statusCohort studyRisk factorsCell percentageVeterans Aging Cohort StudyDevelopment of HCCCurrent HIV RNADetectable HIV viremiaHepatitis C coinfectionAging Cohort StudyDiagnosis of cirrhosisLonger durationDetectable HIVLow CD4C coinfectionCurrent CD4Hazard ratioCancer RegistryAssociation of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada
Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessol NA, Achenbach CJ, Brooks JT, Gill MJ, Grover S, Horberg MA, Li J, Mathews WC, Mayor AM, Patel P, Rabkin CS, Rachlis A, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R, Benson C, Bosch R, Kirk G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Rabkin C, Margolick J, Jacobson L, D’Souza G, Klein M, Kroch A, Burchell A, Betts A, Lindsay J, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Mathews W, Eron J, Napravnik S, Kitahata M, Crane H, Drozd D, Sterling T, Haas D, Rebeiro P, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Freeman A, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Lee J, You B, Hogan B, Zhang J, Jing J, Humes E, Coburn S. Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases 2019, 70: 1176-1185. PMID: 31044245, PMCID: PMC7319056, DOI: 10.1093/cid/ciz329.Peer-Reviewed Original ResearchConceptsAnal cancer riskHIV RNA measuresCancer riskPeak CD4North American AIDS Cohort CollaborationRNA measuresHIV-1 RNA levelsHuman immunodeficiency virus (HIV) viremiaOncogenic human papillomavirus (HPV) infectionAnal cancer developmentAssociation of immunosuppressionTime-updated CD4T-cell countsHuman papillomavirus infectionHuman immunodeficiency virusCohort CollaborationPapillomavirus infectionImmunodeficiency virusImmunoregulatory controlCD4Cox modelCancer promotionUseful markerCancer developmentRNA levelsWhat Does Aging with HIV Mean for Nursing Homes?
Justice AC, Akgün KM. What Does Aging with HIV Mean for Nursing Homes? Journal Of The American Geriatrics Society 2019, 67: 1327-1329. PMID: 31063666, PMCID: PMC6612581, DOI: 10.1111/jgs.15950.Peer-Reviewed Original ResearchConceptsNursing homesPredictors of timely opioid agonist treatment initiation among veterans with and without HIV
Wyse JJ, Robbins JL, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Gaither JR, Gordon K, Skanderson M, Barry DT, Crystal S, Justice A, Kraemer KL. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug And Alcohol Dependence 2019, 198: 70-75. PMID: 30878769, PMCID: PMC6836871, DOI: 10.1016/j.drugalcdep.2019.01.038.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyOAT initiationUninfected patientsClinical encountersNational observational cohortAging Cohort StudyAfrican American patientsImproved health outcomesAgonist therapyCohort studyObservational cohortTreatment initiationPredictive factorsEffective treatmentAdjusted modelUninfected controlsUse disordersPsychiatric diagnosisPWHClinical practicePatientsHealth outcomesRural residence
2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2017
Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States
Wong C, Gange SJ, Moore RD, Justice AC, Buchacz K, Abraham AG, Rebeiro PF, Koethe JR, Martin JN, Horberg MA, Boyd CM, Kitahata MM, Crane HM, Gebo KA, Gill MJ, Silverberg MJ, Palella FJ, Patel P, Samji H, Thorne J, Rabkin CS, Mayor A, Althoff KN, Freeman A, Cescon A, Rachlis A, Rogers B, Rodriguez B, Grasso C, Benson C, Drozd D, Fiellin D, Haas D, Kirk G, Willig J, Globerman J, Brooks J, Eron J, Montaner J, Gabler K, Anastos K, Mayer K, Jacobson L, Kopansky-Giles M, Klein M, Turner M, Mugavero M, Saag M, Harrigan P, Dubrow R, Hunter-Mellado R, Hogg R, Bosch R, McKaig R, Bebawy S, Rourke S, Napravnik S, Boswell S, Sterling T. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases 2017, 66: 1230-1238. PMID: 29149237, PMCID: PMC5889007, DOI: 10.1093/cid/cix998.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBlack PeopleCohort StudiesDiabetes Mellitus, Type 2FemaleHeterosexualityHIVHIV InfectionsHomosexuality, MaleHumansHypercholesterolemiaHypertensionLongitudinal StudiesMaleMiddle AgedMultimorbidityRenal Insufficiency, ChronicSexual and Gender MinoritiesUnited StatesWhite PeopleConceptsHuman immunodeficiency virusAdjusted prevalence ratiosAge-associated conditionsImmunodeficiency virusMultimorbidity prevalenceClinical careNorth American AIDS Cohort CollaborationEnd-stage liver diseaseMedian baseline ageHIV outpatient clinicChronic kidney diseaseRobust error varianceConfidence intervalsComplex healthcare needsDemographic subgroupsCohort CollaborationComorbidity preventionCohort studyDiabetes mellitusLiver diseaseOutpatient clinicKidney diseasePrevalence ratiosBaseline ageCare complexity
2016
D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events
Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O’Bryan T, Rimland D, Justice AC, Agan BK, . D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLOS ONE 2016, 11: e0152588. PMID: 27088215, PMCID: PMC4835105, DOI: 10.1371/journal.pone.0152588.Peer-Reviewed Original ResearchConceptsNon-AIDS diseasesNon-AIDS eventsD-dimer levelsHIV viral suppressionART initiationAntiretroviral therapyViral suppressionD-dimerInterleukin-6Time pointsUS Military HIV Natural History StudyMulticenter observational cohortMedian CD4 countIL-6 levelsMean percent increaseActive duty military personnelNatural history studiesDuty military personnelCD4 countHIV seroconversionHIV levelsMedian durationObservational cohortMedian timeExcess risk
2014
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNA
2011
Cancer Screening in Patients Infected with HIV
Sigel K, Dubrow R, Silverberg M, Crothers K, Braithwaite S, Justice A. Cancer Screening in Patients Infected with HIV. Current HIV/AIDS Reports 2011, 8: 142-152. PMID: 21695529, PMCID: PMC3307131, DOI: 10.1007/s11904-011-0085-5.Peer-Reviewed Original ResearchConceptsCancer screening interventionsCancer screeningScreening interventionsGeneral populationHIV clinical practiceAnal cancerHodgkin's lymphomaLung cancerHepatocellular carcinomaHIVClinical practicePatientsEnhanced riskScreening testHealth maintenanceSpecific cancersCancerHealth concernLife expectancyGood evidenceParticular cancerLymphomaRiskScreeningIntervention
2009
Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America
Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD, Research and Design N. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. Clinical Infectious Diseases 2009, 49: 1582-1590. PMID: 19845473, PMCID: PMC2871149, DOI: 10.1086/644768.Peer-Reviewed Original ResearchConceptsPlasma HIV RNA levelsCombination antiretroviral therapyHIV RNA levelsVirologic failureRegimen failureHistory of AIDSAntiretroviral therapyTreatment failureHigher plasma HIV RNA levelsAbility of therapyRNA levelsT-cell countsTreatment-naive patientsIndependent risk factorMultivariate Cox regressionAggressive therapeutic interventionMore effective optionsModified therapyHIV infectionCox regressionRisk factorsT cellsSubsequent mortalityMortality rateClinical practiceMortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal Of Epidemiology 2009, 38: 1624-1633. PMID: 19820106, PMCID: PMC3119390, DOI: 10.1093/ije/dyp306.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCause of DeathCD4 Lymphocyte CountCohort StudiesFemaleHIVHIV InfectionsHomosexuality, MaleHumansMaleMortalityPrevalenceProspective StudiesRisk FactorsSubstance Abuse, IntravenousViral LoadVirus ReplicationConceptsCD4 cell countAntiretroviral therapyCells/microLGeneral populationCell countEligible patientsExcess mortalityCopies/Start of ARTViral replicationART Cohort CollaborationCorresponding general populationMortality of HIVPotent antiretroviral therapyCombination antiretroviral therapyPercentage of patientsProspective cohort studyInjection drug useViral load measurementsNumber of deathsCohort CollaborationCohort studyMedian ageViral loadClinical stageEffect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal Of Medicine 2009, 360: 1815-1826. PMID: 19339714, PMCID: PMC2854555, DOI: 10.1056/nejmoa0807252.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyRisk of deathAsymptomatic patientsHuman immunodeficiency virus (HIV) infectionCubic millimeterEarly-therapy groupImmunodeficiency virus infectionPrevious antiretroviral therapyCohort of patientsClinical characteristicsHIV infectionRelative riskEarly initiationVirus infectionCD4PatientsMedical careTherapyDeathCalendar yearInfectionRiskCountSurvivalGroup